

# Timothy A Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6828850/publications.pdf>

Version: 2024-02-01

172  
papers

45,580  
citations

8755

75  
h-index

5829

161  
g-index

183  
all docs

183  
docs citations

183  
times ranked

49953  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. <i>Molecular Cancer Research</i> , 2022, 20, 45-55.	3.4	13
2	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	17.5	110
3	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 382-394.	4.1	6
4	Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients. <i>Aging Cell</i> , 2022, 21, e13544.	6.7	11
5	Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. <i>Cancer Research</i> , 2022, 82, 2076-2083.	0.9	18
6	Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2022, 6, 23.	5.4	17
7	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. <i>Neoplasia</i> , 2022, 28, 100790.	5.3	5
8	Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade. <i>JAMA Network Open</i> , 2022, 5, e220448.	5.9	26
9	H3K9 methylation drives resistance to androgen receptor antagonist therapy in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114324119.	7.1	21
10	Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. <i>Nature Immunology</i> , 2022, 23, 904-915.	14.5	39
11	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	9
12	Mitochondrial genotype remodels the metabolic and microenvironmental landscape of Hurthle cell carcinoma. <i>Science Advances</i> , 2022, 8, .	10.3	15
13	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	10
14	The status of tumor mutational burden and immunotherapy. <i>Nature Cancer</i> , 2022, 3, 652-656.	13.2	48
15	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	9.4	7
16	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <i>Nature Genetics</i> , 2022, 54, 996-1012.	21.4	30
17	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	6.3	38
18	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	3.1	28

#	ARTICLE	IF	CITATIONS
19	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	21.4	139
20	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	6.3	98
21	Precision regenerative medicine. <i>Stem Cell Research and Therapy</i> , 2021, 12, 39.	5.5	8
22	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	12.8	212
23	Immunotherapy biomarkers: the long and winding road. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 323-324.	27.6	14
24	Qa-1b Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. <i>Molecular Cancer Research</i> , 2021, 19, 1076-1084.	3.4	11
25	Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity. <i>JAMA Network Open</i> , 2021, 4, e217746.	5.9	29
26	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	3.4	20
27	Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). <i>Pharmaceuticals</i> , 2021, 14, 447.	3.8	32
28	Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. <i>JAMA Oncology</i> , 2021, 7, 739.	7.1	125
29	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	16.8	179
30	Resource-efficient pooled sequencing expands translational impact in solid tumors. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021, 19, 18-23.	0.1	1
31	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	7.0	12
32	Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 292.	17.1	13
33	Pursuing Immunotherapeutic Targets in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1056-1057.	1.1	0
34	Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker—Reply. <i>JAMA Oncology</i> , 2021, 7, 1245.	7.1	0
35	Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. <i>Science Translational Medicine</i> , 2021, 13, eabg4328.	12.4	8
36	My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. <i>Genome Biology</i> , 2021, 22, 53.	8.8	11

#	ARTICLE	IF	CITATIONS
37	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 1516-1525.	7.0	6
38	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	1.4	27
39	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 3628-3644.	1.4	3
40	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. <i>Nature Communications</i> , 2021, 12, 6821.	12.8	15
41	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 112-115.	3.3	47
42	Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.	10.7	121
43	TGF- $\beta$ 2 suppresses type 2 immunity to cancer. <i>Nature</i> , 2020, 587, 115-120.	27.8	137
44	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. <i>Human Molecular Genetics</i> , 2020, 29, R214-R225.	2.9	3
45	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	3.8	76
46	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	13.2	114
47	Genetic and environmental determinants of human TCR repertoire diversity. <i>Immunity and Ageing</i> , 2020, 17, 26.	4.2	42
48	HIF-1 $\alpha$ and HIF-2 $\alpha$ differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. <i>Nature Communications</i> , 2020, 11, 4111.	12.8	141
49	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	12.8	46
50	Diverse Neoantigens and the Development of Cancer Therapies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 113-128.	2.2	15
51	Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. <i>Science Advances</i> , 2020, 6, eaaz3221.	10.3	67
52	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1221.	3.7	46
53	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
54	Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 110, 104877.	1.5	22

#	ARTICLE	IF	CITATIONS
55	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 2859-2870.	7.0	75
56	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
57	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	7.0	30
58	Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. <i>JCI Insight</i> , 2020, 5, .	5.0	95
59	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2712-2726.	8.2	112
60	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. <i>PLoS Biology</i> , 2020, 18, e3000970.	5.6	139
61	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
62	Title is missing!. , 2020, 18, e3000970.		0
63	Title is missing!. , 2020, 18, e3000970.		0
64	Title is missing!. , 2020, 18, e3000970.		0
65	Title is missing!. , 2020, 18, e3000970.		0
66	Title is missing!. , 2020, 18, e3000970.		0
67	Title is missing!. , 2020, 18, e3000970.		0
68	Title is missing!. , 2020, 18, e3000970.		0
69	CD97 is a critical regulator of acute myeloid leukemia stem cell function. <i>Journal of Experimental Medicine</i> , 2019, 216, 2362-2377.	8.5	24
70	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 96, 140-147.	1.5	46
71	The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy. <i>Genome Medicine</i> , 2019, 11, 43.	8.2	16
72	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	1.8	8

#	ARTICLE	IF	CITATIONS
73	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
74	RIG-I activation is critical for responsiveness to checkpoint blockade. <i>Science Immunology</i> , 2019, 4, .	11.9	80
75	Lung Cancer Evolution: What's Immunity Got to Do with It?. <i>Cancer Cell</i> , 2019, 35, 711-713.	16.8	6
76	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	30.7	282
77	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	12.6	395
78	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. <i>Nature</i> , 2019, 569, 270-274.	27.8	1,528
79	High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 523-528.	2.9	4
80	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	28.4	1,657
81	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. <i>Nature Communications</i> , 2019, 10, 943.	12.8	132
82	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 1715-1720.	30.7	194
83	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. <i>Neuro-Oncology</i> , 2019, 21, 189-200.	1.2	49
84	Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. <i>Cancer Discovery</i> , 2019, 9, 510-525.	9.4	169
85	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
86	Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 1226-1232.	7.0	26
87	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 4276-4289.	8.2	134
88	RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade. <i>Blood</i> , 2019, 134, 624-624.	1.4	1
89	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1386-1392.	6.3	137
90	ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis. <i>Cancer Immunology Research</i> , 2018, 6, 151-162.	3.4	42

#	ARTICLE	IF	CITATIONS
91	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. <i>Clinical Cancer Research</i> , 2018, 24, 963-971.	7.0	57
92	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. <i>BMC Cancer</i> , 2018, 18, 225.	2.6	28
93	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. <i>Nature Communications</i> , 2018, 9, 1057.	12.8	66
94	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	12.6	834
95	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	1.6	39
96	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1688-1698.	10.7	119
97	ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. <i>Nature Communications</i> , 2018, 9, 4158.	12.8	138
98	The hallmarks of successful anticancer immunotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	419
99	Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 833-844.	0.8	1
100	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. <i>Trends in Immunology</i> , 2018, 39, 536-548.	6.8	152
101	Integrated Genomic Analysis of H <sup>1</sup> le Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	16.8	195
102	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. <i>Nature Genetics</i> , 2018, 50, 62-72.	21.4	137
103	Transcriptional Mechanisms of Resistance to Anti-“PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	7.0	67
104	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>MED12</i> and <i>RBM10</i> as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017, 23, 5970-5980.	7.0	89
105	Dissecting microsatellite instability in colorectal cancer: one size does not fit all. <i>Genome Medicine</i> , 2017, 9, 45.	8.2	4
106	Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5 Å– 6 Gy) conformal radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 203-208.	0.6	16
107	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. <i>Clinical Cancer Research</i> , 2017, 23, 4429-4440.	7.0	142
108	Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. <i>Neoplasia</i> , 2017, 19, 75-83.	5.3	27

#	ARTICLE	IF	CITATIONS
109	Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. <i>Clinical Cancer Research</i> , 2017, 23, 3109-3119.	7.0	23
110	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	12.8	77
111	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	28.9	1,515
112	NF- $\kappa$ B c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. <i>Cell</i> , 2017, 170, 1096-1108.e13.	28.9	222
113	An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. <i>Cell Reports</i> , 2017, 20, 1623-1640.	6.4	96
114	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> , 2017, 551, 512-516.	27.8	854
115	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <i>Nature</i> , 2017, 551, 517-520.	27.8	532
116	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 797-804.	0.8	40
117	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	7.1	191
118	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
119	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in <i>ATM</i> . <i>Oncotarget</i> , 2017, 8, 10312-10323.	1.8	31
120	PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. <i>Oncotarget</i> , 2017, 8, 15827-15837.	1.8	14
121	The head and neck cancer immune landscape and its immunotherapeutic implications. <i>JCI Insight</i> , 2016, 1, e89829.	5.0	569
122	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. <i>Oncotarget</i> , 2016, 7, 3403-3415.	1.8	306
123	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> , 2016, 7, 10051-10063.	1.8	247
124	Corticosteroids compromise survival in glioblastoma. <i>Brain</i> , 2016, 139, 1458-1471.	7.6	271
125	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	7.0	153
126	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	7.0	95



#	ARTICLE	IF	CITATIONS
127	Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. <i>Cancer Cell</i> , 2016, 29, 737-750.	16.8	50
128	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 703-713.	9.4	92
129	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <i>Nature Genetics</i> , 2016, 48, 1327-1329.	21.4	115
130	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. <i>Cancer Research</i> , 2016, 76, 6495-6506.	0.9	105
131	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	8.8	746
132	FAT1 mutations cause a glomerulotubular nephropathy. <i>Nature Communications</i> , 2016, 7, 10822.	12.8	99
133	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1048929.	0.7	31
134	Regularized quantile regression under heterogeneous sparsity with application to quantitative genetic traits. <i>Computational Statistics and Data Analysis</i> , 2016, 95, 222-239.	1.2	22
135	Immunotherapy and Oncogenic Pathways: The PTEN Connection. <i>Cancer Discovery</i> , 2016, 6, 128-129.	9.4	17
136	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469.	12.6	2,445
137	Integrated genomic characterization of IDH1-mutant glioma malignant progression. <i>Nature Genetics</i> , 2016, 48, 59-66.	21.4	253
138	Cancer Neoantigens and Applications for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 807-812.	7.0	188
139	CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function. <i>Blood</i> , 2016, 128, 1077-1077.	1.4	3
140	ATPS-44INHIBITION OF POLO-LIKE KINASE 1 SENSITIZESISOCITRATE DEHYDROGENASE 1MUTANT ASTROCYTES TO TEMOZOLOMIDE TREATMENT. <i>Neuro-Oncology</i> , 2015, 17, v27.5-v28.	1.2	0
141	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. <i>PLoS ONE</i> , 2015, 10, e0135750.	2.5	51
142	Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 368-375.	0.8	334
143	Immunogenic peptide discovery in cancer genomes. <i>Current Opinion in Genetics and Development</i> , 2015, 30, 7-16.	3.3	63
144	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	27.0	2,582

#	ARTICLE	IF	CITATIONS
145	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	12.6	6,756
146	Genetics and immunology: reinvigorated. <i>OncolImmunology</i> , 2015, 4, e1029705.	4.6	7
147	Genomic landscape of adenoid cystic carcinoma of the breast. <i>Journal of Pathology</i> , 2015, 237, 179-189.	4.5	133
148	Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 125, 149-156.	2.9	224
149	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	28.9	1,408
150	Remodeling of the Methylation Landscape in Breast Cancer Metastasis. <i>PLoS ONE</i> , 2014, 9, e103896.	2.5	43
151	Survival of patients treated with radiation therapy for anaplastic astrocytoma. <i>Radiology and Oncology</i> , 2014, 48, 381-386.	1.7	8
152	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. <i>Cancer Biology and Therapy</i> , 2014, 15, 623-632.	3.4	27
153	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	27.0	3,753
154	Antitumour immunity gets a boost. <i>Nature</i> , 2014, 515, 496-498.	27.8	90
155	Transcriptional diversity of long-term glioblastoma survivors. <i>Neuro-Oncology</i> , 2014, 16, 1186-1195.	1.2	69
156	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. <i>Nature Genetics</i> , 2014, 46, 588-594.	21.4	144
157	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
158	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. <i>Genes and Diseases</i> , 2014, 1, 75-86.	3.4	78
159	Outcomes and Prognostic Factors in Women With 1 to 3 Breast Cancer Brain Metastases Treated With Definitive Stereotactic Radiosurgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 518-525.	0.8	28
160	A Phase 2 Trial of Stereotactic Radiosurgery Boost After Surgical Resection for Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 130-136.	0.8	218
161	Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 322-329.	0.8	91
162	Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules. <i>Cell</i> , 2014, 156, 603-616.	28.9	241

#	ARTICLE	IF	CITATIONS
163	Deletion of <i>Ptprd</i> and <i>Cdkn2a</i> cooperate to accelerate tumorigenesis. <i>Oncotarget</i> , 2014, 5, 6976-6982.	1.8	22
164	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. <i>Science</i> , 2013, 340, 626-630.	12.6	1,014
165	The mutational landscape of adenoid cystic carcinoma. <i>Nature Genetics</i> , 2013, 45, 791-798.	21.4	394
166	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. <i>Nature Medicine</i> , 2013, 19, 901-908.	30.7	388
167	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. <i>Oncotarget</i> , 2013, 4, 1737-1747.	1.8	141
168	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. <i>Oncotarget</i> , 2013, 4, 1729-1736.	1.8	213
169	IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. <i>Clinical Cancer Research</i> , 2012, 18, 2490-2501.	7.0	127
170	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. <i>Nature</i> , 2012, 483, 479-483.	27.8	1,668
171	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature</i> , 2012, 483, 474-478.	27.8	1,693
172	Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. <i>Oncotarget</i> , 2012, 3, 1194-1203.	1.8	241